T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges

Paczesny et al. review why bispecific antibodies, successful in other blood cancers, have lagged in acute myeloid leukemia. They highlight how limited tumor specificity and toxicity hinder progress and outline emerging targets and engineering strategies that could enable safer, more effective immunotherapies for this hard-to-treat disease.